You are here
Articles
Posted on Thursday, July 10, 2014 - 2:17pm
Ghalaut VS1, Sangwan L, Dahiya K, Ghalaut PS, Dhankhar R, Saharan R.
Posted on Thursday, July 10, 2014 - 1:14pm
M Agrawal1, B Hanfstein1, P Erben1, D Wolf2, T Ernst3, A Fabarius1, S Saussele1, D Purkayastha4, R C Woodman4, W-K Hofmann1, R Hehlmann1, A Hochhaus3 and M C Müller1
Nilotinib was able to impede proliferation of MDR1-...
Posted on Tuesday, July 8, 2014 - 1:41pm
Timothy P. Hughes1,*, Jeffrey H. Lipton2, Nelson Spector3, Francisco Cervantes4, Ricardo Pasquini5, Nelma Cristina D. Clementino6, Pedro Enrique Dorlhiac Llacer7, Anthony P. Schwarer8, Francois-Xavier Mahon9, Delphine...
Posted on Tuesday, July 8, 2014 - 1:24pm
Josu de la Fuente,1 Andre Baruchel,2 Andrea Biondi,3 Eveline de Bont,4 Marie-Francoise Dresse,5 Meinolf Suttorp6 and
Frederic Millot7 on behalf of the International BFM Group (iBFM) Study Group Chronic Myeloid Leukaemia...
Posted on Friday, June 20, 2014 - 11:30am
Jane de Lartigue, PhD Published Online: Monday, May 12, 2014
Renier J. Brentjens, MD, PhD, director of Cellular Therapeutics at Memorial Sloan Kettering (MSK) Cancer Center, focuses on the development of new...
Posted on Friday, June 20, 2014 - 11:23am
F Hayakawa1, K Sugimoto1,2, Y Harada2, N Hashimoto2, N Ohi2, S Kurahashi1 and T Naoe1
"Here, we demonstrated that a novel STAT3 inhibitor, OPB-31121, strongly inhibited not only STAT3 but also STAT5 phosphorylation. OPB...
Posted on Monday, June 9, 2014 - 1:49pm
Susan Branford1,*, David T. Yeung2, Wendy T. Parker1, Nicola D. Roberts1, Leanne Purins1, Jodi A. Braley1, Haley K. Altamura1, Alexandra L. Yeoman1, Jasmina Georgievski1, Bronte A. Jamison1, Stuart Phillis1, Zoe...
Posted on Thursday, May 15, 2014 - 1:41pm
Carlo Gambacorti-Passerini,1
* Tim H. Brummendorf, 2,3 Dong-Wook Kim,4 Anna G. Turkina,5 Tamas Masszi,6
Posted on Thursday, May 15, 2014 - 12:46pm
L. Legros, J. Guilhot, S. Huault, F.X. Mahon, C. Preudhomme, F. Guilhot, A.O. Hueber, from the French CML Group (FI-LMC)
Posted on Thursday, May 8, 2014 - 2:38pm
David M. Ross1,2,3,4, Susan Branford5, John F. Seymour2,6, Anthony P. Schwarer2,7, Christopher Arthur2,8, David T. Yeung1,2,3, Phuong Dang1, Jarrad M. Goyne1, Cassandra Slader9, Robin J. Filshie2,10, Anthony K. Mills2,...
Posted on Friday, April 4, 2014 - 12:45pm
Michael Lauseker1,Joerg Hasford1, Markus Pfirrmann1, and Rüdiger Hehlmann2
Key points
* Chronic myeloid leukemia patients enjoyed superior survival chances when treated in teaching hospitals.
Posted on Wednesday, March 12, 2014 - 3:39pm
Neil P. Shah1,*, François Guilhot2, Jorge E. Cortes3, Charles A. Schiffer4, Philipp le Coutre5, Tim H. Brümmendorf6, Hagop M. Kantarjian3, Andreas Hochhaus7, Philippe Rousselot8, Hesham Mohamed9, Diane Healey10, Michael...
Posted on Tuesday, March 4, 2014 - 12:54pm
*Clinical Care Options: Oncology.
Posted on Tuesday, February 11, 2014 - 12:20pm
London, UK, January 09, 2014 --
The Avillion Group (Avillion), a co-developer of late-stage clinical assets, announced today that it has entered into an exclusive collaborative development agreement with Pfizer Inc. to...
Posted on Friday, January 31, 2014 - 1:12pm
Michele Baccarani1, Michael W. Deininger2, Gianantonio Rosti3, Andreas Hochhaus4, Simona Soverini3, Jane F. Apperley5, Francisco Cervantes6, Richard E. Clark7, Jorge E. Cortes8, François Guilhot9, Henrik Hjorth-Hansen10...
- ‹ previous
- 8 of 29
- next ›